Organovo Holdings, Inc. (LON: 0R02)
London flag London · Delayed Price · Currency is GBP · Price in USD
0.363
-0.017 (-4.40%)
Jan 22, 2025, 3:53 PM BST

Organovo Holdings Company Description

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.

Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

The company’s lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis.

Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters.

The company was incorporated in 2007 and is headquartered in San Diego, California.

Organovo Holdings, Inc.
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 20

Contact Details

Address:
11555 Sorrento Valley Road
San Diego, Delaware 92121
United States
Phone 858 224 1000
Website organovo.com

Stock Details

Ticker Symbol 0R02
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year April - March
Reporting Currency USD
ISIN Number US68620A2033
SIC Code 2836

Key Executives

Name Position
Keith E. Murphy Executive Chairman and Corporate Secretary
Vaidehi Joshi Director of Discovery Biology and Director
Norman Staskey President, Chief Financial Officer and Principal Financial Officer
Dr. Curtis M. Tyree Ph.D. Senior Vice President of Strategy and Business Development